These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. Monach PA; Warner RL; Tomasson G; Specks U; Stone JH; Ding L; Fervenza FC; Fessler BJ; Hoffman GS; Iklé D; Kallenberg CG; Krischer J; Langford CA; Mueller M; Seo P; St Clair EW; Spiera R; Tchao N; Ytterberg SR; Johnson KJ; Merkel PA Ann Rheum Dis; 2013 Aug; 72(8):1342-50. PubMed ID: 22975753 [TBL] [Abstract][Full Text] [Related]
7. Suitability of reduced dose glucocorticoids therapy regimen for antibody-associated vasculitis patients with TB: a retrospective study. Wen R; Xiao J; Ding N; Zhong Y; Yuan Q; Li J; Wang Q; Xie H; Qin J Eur J Clin Microbiol Infect Dis; 2024 Jun; 43(6):1061-1072. PubMed ID: 38536523 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. Jayne D; Blockmans D; Luqmani R; Moiseev S; Ji B; Green Y; Hall L; Roth D; Henderson RB; Merkel PA; Arthritis Rheumatol; 2019 Jun; 71(6):952-963. PubMed ID: 30666823 [TBL] [Abstract][Full Text] [Related]
9. Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Pepper RJ; Draibe JB; Caplin B; Fervenza FC; Hoffman GS; Kallenberg CG; Langford CA; Monach PA; Seo P; Spiera R; William St Clair E; Tchao NK; Stone JH; Specks U; Merkel PA; Salama AD; Arthritis Rheumatol; 2017 Jan; 69(1):185-193. PubMed ID: 27428710 [TBL] [Abstract][Full Text] [Related]
10. Increased levels of neutrophil extracellular trap remnants in the circulation of patients with small vessel vasculitis, but an inverse correlation to anti-neutrophil cytoplasmic antibodies during remission. Söderberg D; Kurz T; Motamedi A; Hellmark T; Eriksson P; Segelmark M Rheumatology (Oxford); 2015 Nov; 54(11):2085-94. PubMed ID: 26170375 [TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U; Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483 [TBL] [Abstract][Full Text] [Related]
19. Rituximab, Cyclophosphamide, and Corticosteroids for ANCA Vasculitis: The Good, the Bad, and the Ugly. Fenoglio R; Roccatello D; Sciascia S Kidney Blood Press Res; 2020; 45(6):784-791. PubMed ID: 33045710 [TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-21 positivity could indicate the current activity of antineutrophil cytoplasmic antibody-associated vasculitis: a monocentric prospective study. Yoon T; Ahn SS; Song JJ; Park YB; Lee SW Clin Rheumatol; 2019 Jun; 38(6):1685-1690. PubMed ID: 30863949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]